Path Therapeutics

Path Therapeutics is a private Canadian neuroscience biotech developing first-in-class therapies for severe childhood epilepsies and other brain disorders. The company uses its proprietary MitoREAD neurometabolic phenotypic drug discovery platform to identify novel drug targets by measuring restoration of mitochondrial function. Its lead program is a phosphodiesterase 4 allosteric modulator being optimized for Dravet syndrome and refractory epilepsy, with preclinical proof-of-concept reported in mouse models. The company was co-founded by Deborah Kurrasch and Jong Rho and is backed at least in part by early support from Viva Biotech/Viva BioInnovator.